Jack Armstrong, MD
Allergy & Immunology · Mechanicsburg, PANPI 1972569911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,850 of the $84,609 with a category attached, or 70.7%. AstraZeneca accounts for 80.0% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2024 at $60,509 and has fallen 94.5% since, to $3,351 in 2025. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,208 payments — averaging $70.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$68K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$1K
- Pfizer$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $8K from 40 others
What the payments were for
- Speaking & faculty fees$59,85071%
- Travel & lodging$1,4782%
- Food & beverage$23,03027%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,609 in reported general payments places this provider in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $82,586 |
| XolairOmalizumab | 25 | $70,414 |
| Dupixent SyringeDupilumab | 15 | $57,979 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $41,492 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $20,854 |
| Spiriva RespimatTiotropium Bromide | 14 | $12,905 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $6,043 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,616 |
| BreynaBudesonide/Formoterol Fumarate | 19 | $4,787 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,765 |
| Montelukast Sodium | 173 | $4,565 |
| Epinephrine | 19 | $4,485 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,432 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,793 |
| Mometasone Furoate | 15 | $2,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,978 | $128,510162 claims |
| Genentech, Inc.Xolair | $125 | $70,41425 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $67,662 | $26,46941 claims |
| Boehringer IngelheimSpiriva Respimat | $273 | $12,90514 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $4,48519 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $195 | $3,79312 claims |
| MerckAsmanex | $57 | $1,66211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Mechanicsburg
- Donald HarperMechanicsburg$142K
- Krista TodoricMechanicsburg$43K
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.